Plaque Psoriasis
Conditions
Brief summary
This trial will be a double-blind, multi-center, randomized, placebo controlled study to evaluate the safety, tolerability, and efficacy of SAN021 study drug when administered for up to 42 days to adults between the ages of 18 to 65 years who have a clinical diagnosis of mild-to-moderate plaque psoriasis.
Detailed description
Patients will enter the Screening Period once the informed consent and photographic consent process has been completed. Patients with mild-to-moderate plaque psoriasis, as defined by a Psoriasis Area and Severity Index (PASI) score between 2 and 12, appropriate for topical treatment that covers a minimum of 1.0% and a maximum of 10% BSA, in the permitted treatment areas, and who meet all of the inclusion and none of the exclusion criteria will be enrolled. Once subject eligibility is confirmed and the screening procedures completed, all enrolled subjects will start the Treatment Period of the study. All enrolled subjects will receive either 10% SAN021 or placebo serum (randomized in a 2:1 ratio) with the first dose applied at the Day 1 Study Visit. Subjects will be instructed on how to apply the study medication twice daily for 42 days. Subjects will return to the clinic for study-related assessments on Study Days 7, 14, 28 and a final visit on Day 42. On Study Day 49, subject will receive a Follow-up phone call and be queried for condition status since going off study.
Interventions
DRUGSAN021 Serum
SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
DRUGSAN021 Placebo
SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
Sponsors
ClinDatrix, Inc.
Clinical Trials of Texas, Inc.
Dermatology Research Center of San Antonio
Derm Research, PLLC
Progressive Clinical Research
Santalis Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Are ≥18 but ≤65 years of age * Have a clinical diagnosis of mild-to-moderate plaque psoriasis, as defined by a Psoriasis Area and Severity Index (PASI) score between 2 and 12, appropriate for topical treatment that covers a minimum of 1.0% and a maximum of 10% Body Surface Area (BSA), in the permitted treatment areas. * Are willing to treat all psoriasis occurring in the permitted treatment areas with only SAN021 * Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. * Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study. * Are willing to refrain from using any lotions, moisturizer, cleansers, cosmetics or creams, other than those issued as part of the study, on the treatment areas during the treatment period. * If female of childbearing potential, must be willing to practice an acceptable form of birth control for the duration of the study. * Are able to give written informed consent in a manner approved by the Institutional Review Board or Ethics Review Committee and comply with the requirements of the study. * Are willing to avoid participation in any other interventional clinical trial for the duration of this study. * Are willing to refrain from treating restricted areas, which will be excluded from the PGA assessments and Body Surface Area (BSA) calculation. These areas are as follows: head, neck, fingernails, toenails, soles of feet, and palms of hands, axillae, or intertriginous areas.
Exclusion criteria
* Have spontaneously improving or rapidly deteriorating plaque psoriasis, or pustular psoriasis as determined by the Investigator. * Have been treated, with prescription medication for plaque psoriasis, with no improvement in condition, within 60 days prior to the Baseline visit. * Are pregnant, breast-feeding, or planning to become pregnant during the study. * Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition. * Are undergoing treatments with topical antipsoriatic drug products other than corticosteroids within 14 days prior to the Baseline Visit, and for therapy containing corticosteroids or retinoids within 28 days prior to Baseline Visit. * Have open sores or open lesions in the treatment area(s). * Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of plaque psoriasis. * Have participated in any interventional clinical trial in the previous 30 days. * Have a known sensitivity to any of the constituents of the test product including sensitivities to sandalwood oil, fragrances, or any member of the Compositae family of vascular plants (e.g., sunflowers, daisies, dahlias, etc.). * Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including oral or parenteral corticosteroids. * Have a history of alcohol or illegal drug/substance abuse, or suspected alcohol or illegal drug/substance abuse in the past 2 years. * Plan to seek alternative treatment of any kind for their psoriasis, in the eligible treatment areas or otherwise, during the trial period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patients Achieving a Physician's Global Assessment of Clear or Almost Clear at Any Time-point From Baseline to Day 42 of the Study | Any time-point from Baseline to Day 42 | The primary preliminary efficacy endpoint will be number of patients achieving a Physician's Global Assessment of clear or almost clear at any time-point during the 42 days of therapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patients Achieving a Psoriasis Area and Severity Index Score Improvement ≥50% at Any Time-point From Baseline to Day 42 of the Study. | Any time-point from Baseline to Day 42 of the study. | Percentage of patients who have a ≥50% reduction in the Psoriasis Area Severity Index (PASI) score at any time-point from Baseline to Day 42 of the study. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| SAN021 Serum SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
SAN021 Serum: SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily. | 46 |
| SAN021 Placebo SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
SAN021 Placebo: SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily. | 23 |
| Total | 69 |
Baseline characteristics
| Characteristic | SAN021 Placebo | Total | SAN021 Serum |
|---|---|---|---|
| Age, Continuous | 47.0 years STANDARD_DEVIATION 11.96 | 44.9 years STANDARD_DEVIATION 11.85 | 43.8 years STANDARD_DEVIATION 11.78 |
| Height | 165.48 cm STANDARD_DEVIATION 12.9841 | 168.45 cm STANDARD_DEVIATION 10.446 | 169.93 cm STANDARD_DEVIATION 8.804 |
| Race/Ethnicity, Customized American Indian/ Alaskan Native | 0 participants | 2 participants | 2 participants |
| Race/Ethnicity, Customized White | 23 participants | 67 participants | 44 participants |
| Region of Enrollment United States | 23 participants | 69 participants | 46 participants |
| Sex: Female, Male Female | 13 Participants | 36 Participants | 23 Participants |
| Sex: Female, Male Male | 10 Participants | 33 Participants | 23 Participants |
| Weight | 84.58 kg STANDARD_DEVIATION 18.352 | 92.61 kg STANDARD_DEVIATION 25.601 | 96.62 kg STANDARD_DEVIATION 27.863 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 46 | 0 / 23 |
| other Total, other adverse events | 4 / 46 | 0 / 23 |
| serious Total, serious adverse events | 2 / 46 | 0 / 23 |
Outcome results
Primary
Patients Achieving a Physician's Global Assessment of Clear or Almost Clear at Any Time-point From Baseline to Day 42 of the Study
The primary preliminary efficacy endpoint will be number of patients achieving a Physician's Global Assessment of clear or almost clear at any time-point during the 42 days of therapy.
Time frame: Any time-point from Baseline to Day 42
Population: The analysis population for this outcome measure is the FAS set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| SAN021 Serum | Patients Achieving a Physician's Global Assessment of Clear or Almost Clear at Any Time-point From Baseline to Day 42 of the Study | 4 Participants |
| SAN021 Placebo | Patients Achieving a Physician's Global Assessment of Clear or Almost Clear at Any Time-point From Baseline to Day 42 of the Study | 3 Participants |
Secondary
Patients Achieving a Psoriasis Area and Severity Index Score Improvement ≥50% at Any Time-point From Baseline to Day 42 of the Study.
Percentage of patients who have a ≥50% reduction in the Psoriasis Area Severity Index (PASI) score at any time-point from Baseline to Day 42 of the study.
Time frame: Any time-point from Baseline to Day 42 of the study.
Population: The analysis set used for this outcome measure is the FAS set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| SAN021 Serum | Patients Achieving a Psoriasis Area and Severity Index Score Improvement ≥50% at Any Time-point From Baseline to Day 42 of the Study. | 6 Participants |
| SAN021 Placebo | Patients Achieving a Psoriasis Area and Severity Index Score Improvement ≥50% at Any Time-point From Baseline to Day 42 of the Study. | 1 Participants |